Renata Medical Receives FDA Approval for the Minima Growth Stent, First-of-its-Kind Device for Treating Aortic Coarctation and Pulmonary Artery Stenosis

Renata Medical today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first-of-its-kind Minima Growth Stent that’s specifically tailored for neonates, infants, and young children, but also designed to be re-expanded over the course of their growth period. This approval marks a groundbreaking advancement in the care of young children facing congenital heart defects, something pediatric cardiologists around the world have been requesting from the medical device industry for over 30 years.¹

“Renata Medical is honored to partner with those helping children born with congenital heart disease,” said Dustin Armer, Co-founder and Chief Executive Officer, Renata Medical. “The approval of the Minima Stent is a huge milestone for our company, achieving the goal of providing the first stent designed and approved for small, growing children that are unfortunately some of the most vulnerable and overlooked patients."

The FDA approved the Minima Stent for treating vessel narrowing – or stenosis – in the aorta or pulmonary arteries. The aorta is responsible for pumping oxygen-rich blood from the heart to the entire body, while the pulmonary arteries pump oxygen-poor blood from the heart to the lungs. A narrowing in either of these arteries may occur naturally or following a surgical intervention. These narrowings can force the heart to work harder. When left untreated, a stenotic aorta or pulmonary artery can lead to heart failure and ultimately, death. For young patients presenting with aortic or pulmonary stenosis, the Minima Stent represents a minimally invasive solution that is designed to be expanded over the course of the child’s life.

Like most interventional procedures, Minima is delivered through the vein or artery in the groin or neck with a small needle. One of the biggest challenges faced by pediatric interventional cardiologists is gaining access to these very small veins and arteries, which can be smaller than a standard straw. Minima's unique design with long, thin frames – or struts – allow it to be crimped down to < 2mm. This proprietary design also helps the stent expand to larger sizes while maintaining enough force to keep the narrowed vessel open. As a result, the majority of patients who receive Minima only need one day in the hospital before they can return home, and when their stent needs expanding, they may go home the same day. “The approval of the Minima Stent is going to have a profound positive effect on our most vulnerable cardiac patients around the world, namely, infants and small children,” said Dr. Evan Zahn, Director of the Congenital Heart Program at Cedars Sinai Medical Center and Chief Medical Officer, Renata Medical. “Having a minimally invasive stent designed specifically to treat these babies and re-expand to keep pace as a child grows is a monumental advancement for our field.”

As part of the approval process, the FDA reviewed findings from the GROWTH Pivotal trial, a prospective, multi-center, non-randomized clinical study to evaluate the safety and effectiveness of the Minima Stent in neonates, infants, and young children. In the study, 97.6% of patients with the Minima Stent had effective stenosis relief, and 100% were free from additional surgical intervention at 6 months following implantation. The study also demonstrated a highly favorable safety profile, with 100% of patients being free of major device-related adverse events through 6 months.

The Minima Stent System uses foundational Growth Technology designed to provide long-term solutions, and Renata Medical plans to leverage this core technology in their pipeline of innovation. Eason Abbott, Co-Founder and Chief Operating Officer, said, “We built the Minima Stent in collaboration with key opinion leaders to provide another option for patients with congenital heart disease. Together, we hope the stent is the first of many devices that improve the outcomes of our smallest patients.”

As of today, the Minima Stent System is commercially available in the U.S.

For U.S. important safety information on the Minima Stent System, visit https://renatamedical.com/minimaifu.

About Renata Medical

Renata Medical, a Delaware corporation, was founded in 2019 with the focus on creating cardiovascular devices for unmet pediatric needs. Renata is committed to innovating, manufacturing, and selling technology that is purposefully created for pediatric patients worldwide.

Connect with us at www.renatamedical.com, LinkedIn, and YouTube.

• Every year, 40,000 children are born with a Congenital Heart Defect (CHD),² but only 3.8% of approved devices are intentionally designed for neonates, infants, and young children.³
• Minima is the first stent system designed, tested, clinically trialed, and now FDA approved for neonates, infants, and young children. It is also designed to expand to larger sizes over the course of the child’s life.
• Data from the GROWTH Pivotal trial demonstrated that patients who received the Minima stent experienced substantial improvement in vessel size and achieved a 98% predetermined success rate.

References:

1. Hatai Y, Nykanen DG, Williams WG, Freedom RM, Benson LN. Endovascular stents in children under 1 year of age: acute impact and late results. Br Heart J. 1995 Dec;74(6):689-95. doi: 10.1136/hrt.74.6.689. PMID: 8541180; PMCID: PMC484136.
2. National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention (2023).
3. Wunnava S, Miller TA, Narang C, Nathan M, Bourgeois FT. US Food and Drug Administration Approval of High-risk Cardiovascular Devices for Use in Children and Adolescents, 1977-2021. JAMA. 2022 Aug 9;328(6):580-582. doi: 10.1001/jama.2022.10041. PMID: 35943478; PMCID: PMC9364120.

Renata Medical and Minima are trademarks of Renata Medical Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240829428051/en/